NCT07857317Not yet recruiting
Non-Contrast Versus Contrast-Enhanced MRI in Colorectal Liver Metastases
Comparative Evaluation of a Non-Contrast Abbreviated MRI Protocol and a Contrast-Enhanced MRI Protocol in Colorectal Liver Metastases
Source: ClinicalTrials.gov · Last updated 5 Oct 2026
Brief summary (registry, in English)
This prospective study aims to compare the diagnostic performance of a non-contrast abbreviated MRI protocol with a contrast-enhanced MRI protocol for the detection and follow-up assessment of colorectal liver metastases.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 27 Sept 2026
- Start date
- 27 Sept 2026
- Primary completion date
- 27 Sept 2027
- Lead sponsor
- Assiut University
- NCT number
- NCT07857317
What you commit to
- Study type: Observational
- Planned participants: 40
- From 27 Sept 2026 to the primary completion date, 27 Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Contraindications to gadolinium-based contrast administration
- Incomplete MRI examinations
- Inadequate image quality preventing reliable assessment
- Contraindications to MRI examination
Who the study is looking for
- \- Histologically confirmed colorectal adenocarcinoma
- One or more hepatic focal lesions known or suspected to represent colorectal liver metastases
- Adequate image quality allowing reliable assessment of hepatic lesions
- Patients scheduled to receive chemotherapy allowing assessment of treatment response
- Patients referred for initial staging, restaging, or evaluation of treatment response
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.